Summary
Moxonidine is an imidazoline receptor modulator, specific for the I1-imidazoline receptor. The stimulation of imidazoline receptors represents a new mode of antihypertensive action to inhibit peripheral alpha-adrenergic tone by a central mechanism. Acute hemodynamic studies reveal moxonidine produces an acute fall of blood pressure and systemic vascular resistance. Heart rate, cardiac output, stroke volume, and pulmonary artery pressures are not affected. Left ventricular end-systolic and diastolic volumes are reduced. Ejection fraction is not significantly affected but 6-month studies showed a regression of left ventricular hypertrophy. After oral administration the maximum concentration of moxonidine is reached in about 1 hour, and elimination half-life is 2.5 hours, prolonged by renal insufficiency. The antihypertensive effect lasts longer than would be expected from the half-life. Open studies with moxonidine have revealed falls between 20 and 29 mmHg systolic, and between 10 and 19 mmHg diastolic blood pressure. In the largest study, over 12 months in 141 patients, most patients were controlled by 0.2mg daily (58%) or 0.2 mg b.i.d. (38%). Moxonidine has been compared with representatives from each important class of antihypertensive drugs. In a crossover trial of clonidine in 20 patients, blood pressure control was similar, but the incidence of tiredness and dry mouth was less on moxonidine, as was the total number of patients experiencing side effects, 85% versus 30% (p<0.01). In a larger parallel group study of moxonidine (n=122) and clonidine (n=30), blood pressure control was similar, but the overall incidence of side effects was less on moxonidine. In comparative studies of moxonidine with atenolol, ACE inhibitors, dihydropyridine calcium antagonists, hydrochlorothiazide, and α1 blockade, the blood pressure control with representatives of these various classes of drugs was similar to moxonidine.
Similar content being viewed by others
References
Chrisp P, Faulds D, Moxonidine: A review of its pharmacology and therapeutic use in essential hypertension.Drugs 1992;44:993–1012.
Ernsberger P, Westbrooks KL, Christen MO, Schafer SG. A second generation of centrally-acting hypertensives on putative I1-imidazoline receptors.J Cardiovasc Pharmacol 1992;20(Suppl 4):S1-S10.
Prichard BNC.Principles and Practice of α-anti-adrenergic Therapy in Cardiovascular Drug Therapy. Messerli FH, ed. Philadelphia: W.B. Sanders, 1990:624–640.
MacPhee GJA, Howie CA, Elliott HL, Reid JL. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects.Br J Clin Pharmacol 1992;33:261–267.
Kirch H, Hutt H-J, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients.J Clin Pharmacol 1990;30:1088–1095.
Mitrovic V, Patyna W, Hüting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension.Cardiovasc Drugs Ther 1991;5:967–972.
Hüting J, Mitrovic V, Bahavar H, Schlepper M. Vergleich der Wirkungen von Monoxidin und Nifedipin auf die links-ventrikuläre Function bei Monotherapie der essentiellen Hypertonie.Herz/Kreislauf 1992;24:132–137.
Eichstädt H, Gatz G, Schröder R, Kreuz D: Linksventrikulare Hypertrophieregression unter einer Therapie mit Moxonidin.J Pharmacol Ther 1991;1:12–17.
Ramage AG, Wilkinson SJ. Evidence that different regional sympathetic outflows vary in their sensitivity to the sympathoinhibitory actions of putative 5-HT1A and α2-adrenoceptor agonists in anaesthetized cats.Br J Pharmacol 1989;98:1157–1164.
Armah BI. Unique presynaptic α2-receptor selectivity and specificity of the anti-hypertensive agent moxonidine.Arzneim-Forsch/Drug Res 1988;38:1435–1442.
Schmidt U, Frerick H, Kraft K, Schenk N, Löw-Kröger A. Hypertension: A possible risk in road traffic.J Cardiovasc Pharmacol 1992;20(Suppl 4):S50-S56.
Weimann HJ, Rudolph M. Clinical pharmacokinetics of moxonidine.J Cardiovasc Pharmacol 1992;20(Suppl 4):S37-S41.
Frisk-Holmberg, Plänitz. A selective alpha2-adrenoceptor agonist in arterial essential hypertension. Clinical experience with moxonidine.Curr Thera Res 1987;42:138–146.
Plänitz V, Kandziora J. Wirksamkeit und Vertraglichkeit des neuen Antihypertensivums Moxonidin bei vorwiegend alteren Patienten.Therapiewoche 1984;34:6426.
Schwartz W, Kandziora J. Langzeiterfahrungen mit Moxonidin, einem neuen Antihypertensivum.Fortschrite Medizin 1990;108:616–620.
Trieb. Open-labelled, uncontrolled multicenter study of the antihypertensive effects of moxonidine in hypertensive patients. Study no. 220-5011. Hannover: Kali-Chemie Pharma 1991.
Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: A comparison.J Cardiovasc Pharmacol 1992;20(Suppl 4):S42-S44.
Lotti G, Gianrossi R. Moxonidine versus captopril in patients with mild to moderate hypertension: Double-blind study on efficacy and safety.Deutsche Medizinische Wochenschrift 1993, submitted.
Ollivier JP, Christen MO, Schäfer SG. Moxonidine: A second generation of centrally acting drugs. An appraisal of clinical experience.J Cardiovasc Pharmacol 1992;20(Suppl 4):S31-S37.
Kraft K, Vetter H. 24 hour blood pressure profile, moxonidine versus captopril. Presented at the European Society of Cardiology, Nice, September 1993.
Plänitz V. Intra-individual comparison of moxonidine and prazosin in hypertensive patients.Eur J Clin Pharmacol 1986;29:645–650.
Prichard BNC, Simmons R, Rooks MJ, Haworth DA, Laws D, Wonnacott S. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension.J Cardiovasc Pharmacol 1992;20(Suppl 4):545–549.
Larat V. Efficacy and tolerance of moxonidine in comparison with a standard therapy with hydrochlorothiazide. In press.
Küppers H. Moxonidine and hydrochlorothiazide in combination, a synergistic anti-hypertensive effect. Presented at the European Society of Cardiology, Nice, September 1993.
Plänitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension.J Clin Pharmacol 1987;27:46–51.
Plänitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension.Eur J Clin Pharmacol 1984;27:147–152.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prichard, B.N.C. Clinical experience with moxonidine. Cardiovasc Drug Ther 8 (Suppl 1), 49–58 (1994). https://doi.org/10.1007/BF00877084
Issue Date:
DOI: https://doi.org/10.1007/BF00877084